Skip to content
Agentic OS
Menu

Intelligence / B2B SaaS / Acquisitions / Lisata Therapeutics, INC.

M&Acompleted an acquisition (SEC 8-K)17 Sept 2026

Lisata Therapeutics, INC.

17 Sept 2026: Completed an acquisition (SEC 8-K) · Pharma and biotech. Recorded in the SEC EDGAR full-text search.

View the source record

Filed
17 Sept 2026
Ticker
LSTA
Role
Completed an acquisition
Sector
Pharma and biotech
Sic
2834
Items
1.01, 2.01, 3.02, 5.02, 5.03, 7.01, 9.01
Summary
On September 17, 2026, the Company completed its acquisition of Marea pursuant to the Merger Agreement. The PIPE Securities were offered and sold in transactions exempt from registration under the Securities Act in reliance on Section 4(a)(2) thereof.
Location
Basking Ridge, NJ
State
New Jersey
Country
United States
SEC CIK
320017
Reference
0001140361-26-036866
What this signal means

Integration means consolidating tools and vendors: the buyer re-platforms the target, and an acquired company's stack is reviewed by its new owner.

  1. Completed an acquisition leads with 189 of 292, then Sold assets or a business (82).
  2. 103 added in the 30 days to 19 Nov 2026.
Reach them with AOS

Find the decision makers at Lisata Therapeutics, INC.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this m&a signal, for your approval.

Start free

More in Completed an acquisition

Acquisitions

See all

Source: SEC EDGAR full-text search, data to 19 Nov 2026. Every Form 8-K reporting Item 2.01 (completion of an acquisition or disposition of assets) filed with the SEC in the last 90 days. The role (buyer, company acquired, seller) is read from the filing's own wording, which is quoted on each row. AOS shows what the public record says; it does not verify or endorse the company.